Job Title

We are an ambitious cyanobacterial biologics platform company seeking an outstanding candidate for the role of Research Scientist. As a highly-motivated individual, you will specialise in the development and testing of novel cyanobacterial biologics, including monoclonal antibodies, VLP vaccines, & therapeutic proteins. You will tackle a range of challenges as an integral part of the team, and demonstrate a high degree of flexibility, creativity, and initiative. You will have team leadership experience, be adaptable, work well collaboratively, and be able to thrive in a start-up environment.Key ResponsibilitiesManagement of lab resources; overseeing smooth functioning of the lab & key processesSupport in vitro & preclinical evaluation of biologics, in collaboration with biochemistry team & CTOWorking with downstream processing lead to coordinate analysis pipelineUpdating CTO and Executive on status and timelines for biologics & preclinical material preparationManaging preclinical material production, in collaboration preclinical testing collaboratorsEducation & ExperienceCriticalBSc or MSc in, Bioscience, Biochemistry, Microbiology, Virology, Pharmacology, Immunology or closely-related areaAt least 1 year experience in experimental work within a life sciences laboratory, such as an academic faculty, research institute, biotechnology or pharmaceutical companyStrong analytical and problem-solving skillsExcellent documentation and communication skills, experience working in a team environmentAdvantageous but not essential:ELISA-based testing & in vitro/in vivo therapeutic characterisationFamiliarity with mAb and/or virus-like particle assembly and purification challengesConducted preclinical development and/or delivery studies of mAbs, vaccines or therapeutic proteinsExperience with mammalian cell culture & mAb expressionUnderstanding & experience of antibody biophysical characterisation techniques, such as disulfide bond formation, LC/HC assembly, and glycosylationAbout the CompanyBondi Bio is an Australian biotechnology company developing a novel platform for the biomanufacture and delivery of biologics using bioengineered cyanobacteria. The platform offers a cost-effective and rapidly-scalable solution to produce monoclonal antibodies, vaccines, and therapeutic proteins. Bondi''s food-grade cyanobacteria has the potential for distributed biomanufacturing and point-of-care needle-free delivery. Bondi is working to bring next-generation biologics to market. #J-18808-Ljbffr